Clinical Trial Update: A Safety and Efficacy Study of XP19986 in Subjects With Spasticity Due to Spinal Cord Injury [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating XP19986 for safety and efficacy in spasticity due to spinal cord injury completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Muscle Spasticity
• Spinal Cord Injury

Drugs mentioned

• XP19986

Snippet

Sponsor: XenoPort, Inc. | Conditions: Muscle Spasticity | Phase 2 | Status: COMPLETED